Grant number: 2025453 | Funding period: 2025 - 2030
Active
S McKeague, TE Lew, A Lowe, L Lau, PA Thompson, A Whitechurch, D Carney, M Wolf, G Reynolds, P Blombery, JF Seymour, AW Roberts, MA Anderson
2026-10-13
Venetoclax was first approved for continuous use in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), but the efficacy..
DM Brander, AW Roberts, TJ Kipps, S Ma, MA Anderson, M Boyer, P Blombery, R Popovic, J Roser, Z Liu, B Chyla, JF Seymour
2025-12-01